288 related articles for article (PubMed ID: 30285127)
1. Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Rheumatology (Oxford); 2019 Mar; 58(3):410-417. PubMed ID: 30285127
[TBL] [Abstract][Full Text] [Related]
2. UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Joint Bone Spine; 2020 Dec; 87(6):647-651. PubMed ID: 32979555
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound in gout: a useful tool for following urate-lowering therapy.
Ottaviani S; Gill G; Aubrun A; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2015 Jan; 82(1):42-4. PubMed ID: 25543275
[TBL] [Abstract][Full Text] [Related]
4. Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective.
Das S; Goswami RP; Ghosh A; Ghosh P; Lahiri D; Basu K
Mod Rheumatol; 2017 May; 27(3):518-523. PubMed ID: 27492663
[TBL] [Abstract][Full Text] [Related]
5. The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients.
El-Mallah R; Ibrahim RA; El Attar EA
Curr Rheumatol Rev; 2022; 18(4):338-345. PubMed ID: 36268549
[TBL] [Abstract][Full Text] [Related]
6. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.
Thiele RG; Schlesinger N
Rheumatol Int; 2010 Feb; 30(4):495-503. PubMed ID: 19543895
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.
Fautrel B; Belhassen M; Hudry C; Woronoff-Lemsi MC; Levy-Bachelot L; Van Ganse E; Tubach F
Joint Bone Spine; 2020 Mar; 87(2):137-139. PubMed ID: 31669808
[TBL] [Abstract][Full Text] [Related]
8. An exploratory ultrasound study of early gout.
Ottaviani S; Allard A; Bardin T; Richette P
Clin Exp Rheumatol; 2011; 29(5):816-21. PubMed ID: 22011529
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
Zhang W; Zhao D; Wu M; Chen W; Jin Z; Zhang H
Ultrasound Med Biol; 2021 Jun; 47(6):1495-1505. PubMed ID: 33785225
[TBL] [Abstract][Full Text] [Related]
10. The value of musculoskeletal ultrasound in predicting gout flares in index joints: A prospective cohort study of people with gout starting urate-lowering therapy.
Han L; Li R; Dalbeth N; Liu M; Yu Q; Jiang C; Ning C; Liu Z; He Y; Li M; Xue X; Jia F; Jia Z; Sun W; Zhang H; Lu J; Wang C; Li C
Semin Arthritis Rheum; 2024 Aug; 67():152418. PubMed ID: 38422901
[TBL] [Abstract][Full Text] [Related]
11. Polyarticular sonographic assessment of gout: a hospital-based cross-sectional study.
Roddy E; Menon A; Hall A; Datta P; Packham J
Joint Bone Spine; 2013 May; 80(3):295-300. PubMed ID: 23142256
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment.
Peiteado D; Villalba A; Martín-Mola E; Balsa A; De Miguel E
Clin Exp Rheumatol; 2017; 35(5):746-751. PubMed ID: 28281462
[TBL] [Abstract][Full Text] [Related]
13. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
[TBL] [Abstract][Full Text] [Related]
14. Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign.
Yuan H; Fan Y; Mou X; Qing Y; Yan X; Tang X; Yue W; Gu P; Yang Q; He Y
Balkan Med J; 2023 Mar; 40(2):104-110. PubMed ID: 36715053
[TBL] [Abstract][Full Text] [Related]
15. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.
Pascual E; Sivera F
Ann Rheum Dis; 2007 Aug; 66(8):1056-8. PubMed ID: 17223663
[TBL] [Abstract][Full Text] [Related]
16. Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy.
Christiansen SN; Østergaard M; Slot O; Keen H; Bruyn GAW; D'Agostino MA; Terslev L
RMD Open; 2020 Jan; 6(1):. PubMed ID: 32396518
[TBL] [Abstract][Full Text] [Related]
17. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
[TBL] [Abstract][Full Text] [Related]
18. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
19. Prediction of renal and cardiometabolic outcomes in gout during urate-lowering therapy by sonography.
Calabuig I; Marty-Ané A; Norberciak L; Budzik JF; Legrand J; Martínez-Sanchis A; Pascart T; Andrés M
Int J Rheum Dis; 2023 Dec; 26(12):2450-2459. PubMed ID: 37786305
[TBL] [Abstract][Full Text] [Related]
20. Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment?
Peiteado D; Villalba A; Martín-Mola E; de Miguel E
Clin Exp Rheumatol; 2015; 33(3):385-90. PubMed ID: 25898174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]